DiagnoCure’s Scientific Partners
Principal Investigator in PrevistageTM GCC clinical study
Daniel J. Sargent, Ph.D.
Daniel J. Sargent, Ph.D., Professor of Biostatistics and Oncology at the Mayo Clinic, is the Group Statistician for the North Central Cancer Treatment Group and the director of Cancer Center Statistics at the Mayo Clinic Comprehensive Cancer Center. He received his BS, MS, and PhD from the University of Minnesota, and has been at Mayo Clinic since graduating in 1996. He is a member of the US Gastrointestinal Cancer Steering Committee, and co-chaired the Gastrointestinal committee for the NCI Common Data Elements Project.
Dr. Sargent co-chaired a joint NCI-EORTC committee on methodology for tumor marker studies, was a member of the FDA panel on endpoints for colon cancer clinical trials, and currently sits on the US NCI Clinical Trials Advisory Committee, which oversees all cancer clinical trials in the United States. Dr. Sargent is a chair or member of over 20 Data Safety and Monitoring Committees.
Dr. Sargent has published papers on innovative designs for Phase I, II, and III clinical trials as well as advances in survival analysis, meta-analysis, and designs for validating tumor biomarkers. He has authored over 150 peer-reviewed manuscripts, book chapters, editorials, and letters.